PapersFlow Research Brief
Potassium and Related Disorders
Research Guide
What is Potassium and Related Disorders?
Potassium and Related Disorders refers to a cluster of medical conditions centered on hyperkalemia management, particularly in patients with kidney diseases, encompassing potassium homeostasis, renin-angiotensin-aldosterone system inhibitors, and treatments like sodium zirconium cyclosilicate and patiromer.
This field includes 26,638 published works on hyperkalemia associations with chronic kidney disease, heart failure, and gastrointestinal adverse events. Research covers electrolyte disorders and therapies such as sodium zirconium cyclosilicate and patiromer. Growth rate over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Hyperkalemia Management in Chronic Kidney Disease
Studies evaluate potassium binder therapies and dietary interventions to control serum potassium in CKD patients. Research assesses recurrence rates, adherence, and renal progression.
Potassium Binders Sodium Zirconium Cyclosilicate
Clinical trials and real-world studies examine SZC's rapid onset, efficacy, and safety in acute/chronic hyperkalemia. Focus includes GI tolerability and use with RAAS inhibitors.
Patiromer in Hyperkalemia Treatment
Researchers investigate patiromer's chronic use for maintaining normokalemia in heart failure and CKD. Analyses cover long-term safety, hypomagnesemia risks, and comparative effectiveness.
RAAS Inhibitors and Hyperkalemia Risk
Epidemiological and mechanistic studies quantify hyperkalemia incidence with ACEi/ARB/MRA use in comorbidities. Research explores risk stratification and mitigation strategies.
Potassium Homeostasis in Heart Failure
This sub-topic dissects dysregulation mechanisms and therapeutic impacts on potassium balance in HFrEF/HFpEF. Studies link fluctuations to arrhythmias and outcomes using biomarkers.
Why It Matters
Hyperkalemia management enables safer use of renin-angiotensin-aldosterone system inhibitors in patients with chronic kidney disease and heart failure, reducing risks of kidney failure and cardiovascular events. In the CREDENCE trial, canagliflozin lowered kidney failure risk in type 2 diabetes patients with nephropathy at 2.62-year median follow-up (Perkovic et al., 2019). Enalapril reduced mortality in severe congestive heart failure, with the CONSENSUS trial showing benefits in NYHA class IV patients (Consensus Trial Study Group, 1987; Swedberg and Kjekshus, 1988). These interventions address cardiorenal syndrome overlaps (Ronco et al., 2008), supporting treatments in high-risk populations.
Reading Guide
Where to Start
"Harrison's Principles of Internal Medicine." (1988) provides foundational coverage of kidney, cardiovascular, and electrolyte disorders, serving as an accessible entry point before specialized trials.
Key Papers Explained
Enalapril trials form a sequence: "Effects of Enalapril on Mortality in Severe Congestive Heart Failure" (Consensus Trial Study Group, 1987) and "Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)" (Swedberg and Kjekshus, 1988) established mortality benefits in severe heart failure, extended by "Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions" (Yusuf, 1992) to early stages. "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy" (Perkovic et al., 2019) builds on these by addressing renal protection amid hyperkalemia risks. "Cardiorenal Syndrome" (Ronco et al., 2008) connects heart-kidney interactions.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes hyperkalemia management with sodium zirconium cyclosilicate and patiromer alongside renin-angiotensin-aldosterone system inhibitors in chronic kidney disease and heart failure. No recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Harrison's Principles of Internal Medicine. | 1988 | Annals of Internal Med... | 12.6K | ✕ |
| 2 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephro... | 2019 | New England Journal of... | 5.6K | ✓ |
| 3 | Effects of Enalapril on Mortality in Severe Congestive Heart F... | 1987 | New England Journal of... | 5.1K | ✕ |
| 4 | Effects of enalapril on mortality in severe congestive heart f... | 1988 | The American Journal o... | 3.8K | ✕ |
| 5 | Effect of Enalapril on Mortality and the Development of Heart ... | 1992 | New England Journal of... | 3.7K | ✕ |
| 6 | Duodenal Infusion of Donor Feces for Recurrent <i>Clostridium ... | 2013 | New England Journal of... | 3.6K | ✓ |
| 7 | SGLT2 inhibitors for primary and secondary prevention of cardi... | 2018 | The Lancet | 2.7K | ✕ |
| 8 | Valsartan, Captopril, or Both in Myocardial Infarction Complic... | 2003 | New England Journal of... | 2.5K | ✓ |
| 9 | Natriuretic Peptides | 1998 | New England Journal of... | 1.9K | ✕ |
| 10 | Cardiorenal Syndrome | 2008 | Journal of the America... | 1.8K | ✕ |
Frequently Asked Questions
What is hyperkalemia in the context of kidney disease?
Hyperkalemia is elevated blood potassium levels often occurring in chronic kidney disease patients. It complicates renin-angiotensin-aldosterone system inhibitor use. Management involves agents like sodium zirconium cyclosilicate and patiromer.
How do renin-angiotensin-aldosterone system inhibitors affect heart failure?
Enalapril reduces mortality in severe congestive heart failure patients (NYHA class IV). The CONSENSUS trial demonstrated improved prognosis with 2.5-40 mg daily dosing (Consensus Trial Study Group, 1987). Similar benefits extend to asymptomatic left ventricular dysfunction (Yusuf, 1992).
What are key treatments for hyperkalemia?
Sodium zirconium cyclosilicate and patiromer are effective potassium-lowering agents. They address hyperkalemia in kidney disease contexts. These therapies support ongoing renin-angiotensin-aldosterone system inhibitor use.
What is cardiorenal syndrome?
Cardiorenal syndrome describes interactions between heart and kidney dysfunction leading to hyperkalemia risks. It involves electrolyte disorders in heart failure and chronic kidney disease. Ronco et al. (2008) outlined its pathophysiology.
How does canagliflozin impact renal outcomes?
Canagliflozin reduces kidney failure and cardiovascular risks in type 2 diabetes with nephropathy. The CREDENCE trial showed lower event rates versus placebo over 2.62 years (Perkovic et al., 2019). This aids hyperkalemia management in comorbid patients.
What role do natriuretic peptides play in potassium disorders?
Natriuretic peptides promote natriuresis and diuresis, influencing potassium homeostasis. Epstein et al. (1998) described their isolation and effects. They relate to heart failure treatments intersecting with hyperkalemia.
Open Research Questions
- ? How can hyperkalemia risks be minimized during long-term renin-angiotensin-aldosterone system inhibitor therapy in chronic kidney disease?
- ? What are the long-term gastrointestinal outcomes of patiromer and sodium zirconium cyclosilicate in heart failure patients?
- ? In cardiorenal syndrome, how do potassium homeostasis disruptions predict mortality beyond current models?
- ? Which patient subgroups with type 2 diabetes benefit most from SGLT2 inhibitors like canagliflozin for hyperkalemia prevention?
- ? What mechanisms link esophageal necrosis to hyperkalemia treatments?
Recent Trends
The field maintains 26,638 works with no specified 5-year growth rate.
Persistent focus remains on hyperkalemia in kidney disease and heart failure, as in foundational papers like Perkovic et al.
2019No recent preprints or news reported.
Research Potassium and Related Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Potassium and Related Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers